New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
08:15 EDTAMPEAmpio's Ampion shows positive results in arthritis study extension
Ampio announced results of the 20 weeks extension of the Ampion SPRING study to be presented at the Western Orthopedic Association Conference in July. This 20-week extension of a multicenter study evaluated the safety and efficacy of a single intra-articular injection of Ampion treatment of inflammation-associated pain in symptomatic OA of the knee. At 20 weeks, the percentage of patients in the moderate-to-severe subgroup who reported a reduction in pain was significantly higher for patients who received Ampion - 50% - compared to those who received vehicle control - 25% -. Similar rates and severity of adverse events were observed in the Ampion and vehicle control groups. A single injection of Ampion was associated with sustained improvements in knee pain over 20 weeks.
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
08:49 EDTAMPEAmpio announces STRIDE study AP008 did not reach its primary endpoint
Ampio Pharmaceuticals announced that the multiple injection STRIDE study AP008 did not reach its primary endpoint against the saline control even though there was a statistically significant reduction in pain compared to baseline for patients receiving Ampion. This pain reduction with Ampion was consistent across all sites and with our previously reported studies Ampion is safe and well tolerated. Ampio Pharmaceuticals launched the Phase III program for AmpionTM to treat pain due to osteoarthritis, OA, of the knee. Each patient received three 4ml intra-articular injections of Ampion, or the saline placebo, one at baseline, the second at two weeks and the third at four weeks. In OA, saline is known to be a partial therapeutic and not a true placebo, but has been the control used in all published OA drug trials.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use